Why Buy Stock In Perspective Therapeutics Inc (CATX)?

Perspective Therapeutics Inc (AMEX:CATX) has a beta value of 1.45 and has seen 5.18 million shares traded in the last trading session. The company, currently valued at $853.66M, closed the last trade at $12.66 per share which meant it lost -$0.59 on the day or -4.45% during that session. The CATX stock price is -50.47% off its 52-week high price of $19.05 and 82.62% above the 52-week low of $2.20. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.18 million shares traded. The 3-month trading volume is 787.62K shares.

The consensus among analysts is that Perspective Therapeutics Inc (CATX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Perspective Therapeutics Inc (AMEX:CATX) trade information

Sporting -4.45% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CATX stock price touched $12.66 or saw a rise of 5.8%. Year-to-date, Perspective Therapeutics Inc shares have moved 214.93%, while the 5-day performance has seen it change -5.17%. Over the past 30 days, the shares of Perspective Therapeutics Inc (AMEX:CATX) have changed -20.08%. Short interest in the company has seen 9.59 million shares shorted with days to cover at 8.97.

Wall Street analysts have a consensus price target for the stock at $20, which means that the shares’ value could jump 36.7% from current levels. The projected low price target is $3.0 while the price target rests at a high of $24.0. In that case, then, we find that the current price level is -89.57% off the targeted high while a plunge would see the stock lose 76.3% from current levels.

Perspective Therapeutics Inc (CATX) estimates and forecasts

Figures show that Perspective Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -13.88% over the past 6 months, with this year growth rate of 37.86%, compared to 19.10% for the industry. Revenue growth from the last financial year stood is estimated to be -87.10%.

7 analysts offering their estimates for the company have set an average revenue estimate of 120k for the current quarter. 7 have an estimated revenue figure of 120k for the next ending quarter. Year-ago sales stood 2.19M and 2.03M respectively for this quarter and the next, and analysts expect sales will shrink by -94.50% for the current quarter and -87.10% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -7.69% over the past 5 years.

CATX Dividends

Perspective Therapeutics Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Perspective Therapeutics Inc (AMEX:CATX)’s Major holders

Insiders own 20.43% of the company shares, while shares held by institutions stand at 57.99% with a share float percentage of 72.88%. Investors are also buoyed by the number of investors in a company, with Perspective Therapeutics Inc having a total of 150.0 institutions that hold shares in the company.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Jun 30, 2024 , the former fund manager holds about 2.51% shares in the company for having 1.69 shares of worth $21.4 million while later fund manager owns 1.27 shares of worth $16.03 million as of Aug 31, 2024 , which makes it owner of about 1.88% of company’s outstanding stock.